Release date: 2009-05-13
Rheumatoid arthritis (RA) is a chronic, etiology of inflammatory synovitis-based systemic disease. It is characterized by hand, small joints of the joints, symmetry, invasive joint inflammation, often associated with external organ involvement and serum rheumatoid factor positive, can lead to joint deformity and loss of function. According to statistics, the incidence of rheumatoid arthritis in women is 2 to 3 times that of men.It can occur at any age, high incidence of age 40 to 60 years old. People who has rheumatoid arthritis in the late, severe or long-term bedridden patients, due to combined infection, gastrointestinal bleeding, heart, lung or kidney disease can be crisis to life. The main purpose of treatment for Rheumatoid arthritis is to reduce the inflammation of the joints, inhibit the development of lesions and irreversible bone destruction, as far as possible to protect the function of joints and muscles, and ultimately achieve complete disease remission or low disease activity target. Treatment principles include 1. Patient education, 2. General treatment 3. Drug treatment 4. Immune purification 5. Functional exercise 6. Surgical treatment. Anti-Rheumatoid Arthritis drug treatment mainly includes non-steroidal anti-inflammatory drugs, slow-acting anti-rheumatic drugs, immunosuppressive agents, immune and biological agents and botanicals. Over the past decade, the treatment of extra-articular lesions and the emergence of new therapies, so that the efficacy of rheumatoid arthritis has been significantly improved. Most patients with rheumatoid arthritis can get a good control or even complete remission.
Anti-Rheumatoid Arthritis Anti-Rheumatoid Arthritis,Rheumatoid Arthritis Diagnosis,Arthritis Treatment,Osteoarthritis Treatment,Best Treatment for Rheumatoid Arthritis,Rheumatoid Arthritis Treatment Drugs Taizhou Volsen Chemical Co., Ltd. , https://www.volsenchem.com
Recently, South China University of Technology has developed an immunoassay kit that can screen patients with influenza A H1N1 at any site. According to the researchers, the kit can be tested on site, without any other equipment, and the results can be obtained within 3-10 minutes. This is a kit validated by the virus of the epidemic strain confirmed by the patient.
It is understood that during the initial response of the H1N1 flu epidemic, Guangzhou Science and Technology Bureau appointed Wang Xiaoning, a professor at the School of Biological Science and Engineering of South China University of Technology, to conduct research, organization and coordination, and organized South China University of Technology Wanfu Biotechnology Co., Ltd. in the South. Based on the research of the Che Xiaoyan research group of Zhujiang Hospital of Medical University, the rapid screening kit for influenza A H1N1 virus was developed. According to the relevant departments of South China University of Technology, after several weeks of research, researchers have developed an immunoassay kit that can screen patients with influenza A H1N1 at any site.
The kit was reviewed on May 8th by the State Key Laboratory of Newly Infectious Diseases, hosted by Academician Yuan Guoyong of the University of Hong Kong. The minimum detection limit for laboratory validation is 1:8000, which is comparable to the level of imported products. The sensitivity is comparable to that of the ELSA kit and can be used for large-scale on-site screening.
Shanghai Medical Device Industry Association